Dipitl (diphenoxylate and atropine): Uses, Dosage & Side Effects

What it's for (Indications)

Diphenoxylate and atropine is indicated as adjunctive therapy in the management of diarrhea.
This medication is primarily used for the symptomatic control of acute and chronic diarrhea of various etiologies, particularly when other non-pharmacological interventions or less potent antidiarrheal agents have proven insufficient or when the underlying cause cannot be immediately or effectively addressed.
It is important to note that this combination drug provides symptomatic relief by reducing bowel motility and improving stool consistency, but it does not treat the underlying cause of diarrhea.
Therefore, its use requires careful consideration of the patient's overall clinical picture, including hydration and electrolyte status, especially in cases of severe or prolonged diarrhea.
It is not intended for the treatment of infectious diarrhea where the causative organism can be eradicated, nor for pseudomembranous colitis associated with broad-spectrum antibiotics, as these conditions require specific treatment and inhibition of gut motility may worsen the disease.

Dosage Information

Type	Guideline
Standard	For adult patients, the typical initial oral dosage of diphenoxylate and atropine is two tablets (each containing 2.5 mg of diphenoxylate hydrochloride and 0.025 mg of atropine sulfate) administered four times daily. This equates to a total daily intake of 20 mg of diphenoxylate hydrochloride. The dosage should be carefully titrated based on the individual patient's response and the severity of their diarrheal symptoms, aiming for the lowest effective dose to control symptoms. Once adequate control of diarrhea is achieved, the dosage may be gradually reduced to a maintenance level, often as low as one to two tablets daily, to minimize potential side effects and the risk of dependence. The maximum recommended daily dosage for adults should not exceed eight tablets (20 mg of diphenoxylate) within a 24-hour period. It is crucial to emphasize that this medication is contraindicated in pediatric patients younger than 6 years of age due to significant risks of respiratory depression and central nervous system (CNS) effects. For pediatric patients aged 6 years and older, dosage must be meticulously calculated based on weight and never exceed adult recommendations, with close monitoring for adverse reactions. Liquid formulations are available for more precise dosing in older children, but caution remains paramount.

Type

Guideline

Standard

For adult patients, the typical initial oral dosage of diphenoxylate and atropine is two tablets (each containing 2.5 mg of diphenoxylate hydrochloride and 0.025 mg of atropine sulfate) administered four times daily. This equates to a total daily intake of 20 mg of diphenoxylate hydrochloride. The dosage should be carefully titrated based on the individual patient's response and the severity of their diarrheal symptoms, aiming for the lowest effective dose to control symptoms. Once adequate control of diarrhea is achieved, the dosage may be gradually reduced to a maintenance level, often as low as one to two tablets daily, to minimize potential side effects and the risk of dependence. The maximum recommended daily dosage for adults should not exceed eight tablets (20 mg of diphenoxylate) within a 24-hour period. It is crucial to emphasize that this medication is contraindicated in pediatric patients younger than 6 years of age due to significant risks of respiratory depression and central nervous system (CNS) effects. For pediatric patients aged 6 years and older, dosage must be meticulously calculated based on weight and never exceed adult recommendations, with close monitoring for adverse reactions. Liquid formulations are available for more precise dosing in older children, but caution remains paramount.

Safety & Warnings

Common Side Effects

The use of diphenoxylate and atropine can elicit a range of side effects, primarily stemming from the opioid-like actions of diphenoxylate and the anticholinergic properties of atropine.
Common adverse effects attributable to diphenoxylate include central nervous system (CNS) manifestations such as dizziness, drowsiness, sedation, headache, and fatigue, as well as gastrointestinal disturbances like nausea, vomiting, abdominal discomfort, and constipation.
Less frequently, patients may experience skin reactions such as rash or pruritus.
The atropine component, even at low doses, can contribute to anticholinergic effects, including dry mouth, blurred vision, urinary retention, and tachycardia, particularly in sensitive individuals or at higher dosages.
More serious, though less common, side effects include respiratory depression, especially with overdose or in vulnerable populations like young children; paralytic ileus; and the potentially life-threatening complication of toxic megacolon, particularly in patients with inflammatory bowel disease.
Prolonged use carries a risk of physical and psychological dependence due to diphenoxylate's opioid-like characteristics, and withdrawal symptoms can occur upon abrupt discontinuation.

Serious Warnings

Black Box Warning: The U.S. Food and Drug Administration (FDA) has issued a Black Box Warning for diphenoxylate and atropine, primarily emphasizing the profound risks associated with its use in pediatric populations. **RESPIRATORY DEPRESSION AND CENTRAL NERVOUS SYSTEM DEPRESSION IN PEDIATRIC PATIENTS** LOMOTIL (diphenoxylate and atropine) is strictly contraindicated in pediatric patients less than 6 years of age due to the documented, severe risks of respiratory depression and profound central nervous system (CNS) depression. Multiple reports have detailed life-threatening respiratory and CNS depression occurring in children under 6 years of age following administration of this medication. Healthcare providers are mandated to monitor pediatric patients aged 6 years and older closely for any signs of respiratory or CNS depression, even when administered within recommended dosage guidelines, given the narrow therapeutic index in this age group. Beyond the pediatric warning, a critical safety concern warranting serious attention is the potential for **TOXIC MEGACOLON**, particularly in individuals with inflammatory bowel disease (IBD), such as ulcerative colitis. The use of antimotility agents like diphenoxylate can paradoxically precipitate or exacerbate toxic megacolon, a severe, potentially fatal complication characterized by acute colonic dilation and systemic toxicity. This risk is notably elevated in patients with acute ulcerative colitis or other forms of severe inflammatory bowel disease. Therefore, diphenoxylate and atropine should be used with extreme caution, if at all, in such patient populations and is often contraindicated in active, severe IBD due to this life-threatening risk. Furthermore, due to diphenoxylate's opioid-like properties, there is a recognized potential for **DRUG DEPENDENCE AND ABUSE**, necessitating careful prescribing and monitoring to mitigate the risks of physical and psychological dependence.
Patients receiving diphenoxylate and atropine require careful monitoring for potential adverse events, especially those affecting the central nervous system (CNS) and gastrointestinal tract.
A significant warning pertains to CNS depression, which can manifest as profound drowsiness, sedation, and respiratory depression, particularly when the medication is co-administered with other CNS depressants such as alcohol, benzodiazepines, barbiturates, or other opioid analgesics.
The risk of toxic megacolon is a critical concern in patients with inflammatory bowel disease (IBD), such as ulcerative colitis.
Administration of antimotility agents can precipitate or exacerbate this severe and potentially fatal complication; thus, extreme caution is warranted, and in many severe cases, its use is contraindicated.
Hepatic impairment can significantly impair the metabolism of diphenoxylate, leading to increased systemic exposure and an elevated risk of adverse effects, including hepatic coma in patients with advanced liver disease; therefore, dosage adjustment or avoidance is crucial.
Patients with severe diarrhea should have their fluid and electrolyte balance meticulously monitored and corrected, as this medication addresses only symptomatic relief and does not replace essential fluid resuscitation.
There is a recognized potential for physical and psychological dependence with prolonged or excessive use of diphenoxylate due to its opioid-like properties, necessitating careful prescribing practices.
Additionally, the anticholinergic effects of atropine can lead to symptoms like blurred vision, urinary retention, and hyperthermia, especially in patients susceptible to anticholinergic side effects or with pre-existing conditions like glaucoma or prostatic hypertrophy.

How it Works (Mechanism of Action)

Diphenoxylate and atropine functions as an antidiarrheal agent through the synergistic actions of its two components. Diphenoxylate, a synthetic opioid derivative structurally analogous to meperidine, exerts its primary therapeutic effect by binding to mu-opioid receptors located within the smooth muscle of the gastrointestinal tract. This binding action inhibits propulsive gastrointestinal motility, thereby significantly increasing intestinal transit time. The delayed transit allows for enhanced reabsorption of water and electrolytes from the intestinal lumen, leading to a reduction in the frequency of bowel movements and an improvement in stool consistency. The atropine sulfate component, present in subtherapeutic doses (0.025 mg per tablet), serves a crucial role as an abuse deterrent. At prescribed dosages, its anticholinergic effects are minimal and typically do not significantly contribute to the antidiarrheal action. However, if the medication is taken in higher-than-recommended doses for recreational purposes, the anticholinergic effects of atropine become pronounced, causing unpleasant symptoms such as severe dry mouth, blurred vision, and flushing, which are intended to discourage intentional overdose or abuse of the diphenoxylate. In addition to its abuse-deterrent role, atropine may also contribute to the overall antidiarrheal effect by further reducing gastrointestinal secretions and motility through its anticholinergic properties, although this contribution is secondary to diphenoxylate's primary action at therapeutic doses.